Semler Scientific faces False Claims Act investigation, shareholder notice issued.

Semler Scientific, Inc. (NASDAQ: SMLR) shareholders who purchased shares between March 10, 2021 and April 15, 2025 may be eligible for a class action lawsuit. The complaint alleges that defendants issued false and/or misleading statements or failed to disclose a material investigation by the US Department of Justice into violations of the False Claims Act.

Semler Scientific, Inc. (NASDAQ: SMLR) shareholders who purchased shares between March 10, 2021 and April 15, 2025 may be eligible for a class action lawsuit. The complaint alleges that defendants issued false and/or misleading statements or failed to disclose a material investigation by the U.S. Department of Justice into violations of the False Claims Act Semler Scientific Inc. (SMLR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit^[1].

The class action lawsuit, filed by Glancy Prongay & Murray LLP, claims that Semler Scientific failed to disclose a material investigation by the U.S. Department of Justice into violations of the False Claims Act, while discussing possible violations in hypothetical terms Semler Scientific Inc. (SMLR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit^[1]. This alleged nondisclosure led to materially misleading statements about the company's business, operations, and prospects Semler Scientific Inc. (SMLR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit^[1].

Semler Scientific and its former distributor, Bard Peripheral Vascular Inc., have agreed to reimburse the U.S. government nearly $37 million for allegedly misrepresenting the reimbursability of tests performed using their devices Semler Scientific, Bard Peripheral Vascular Settle Medicare Fraud Claims^[3]. The settlement resolves allegations that Semler and Bard falsely claimed that tests conducted using the FloChec and QuantaFlo devices were reimbursable by Medicare, causing healthcare providers to submit false claims to Medicare Semler Scientific, Bard Peripheral Vascular Settle Medicare Fraud Claims^[3].

Investors are advised to contact Glancy Prongay & Murray LLP or Pomerantz LLP to inquire about their rights or interests in this matter Semler Scientific Inc. (SMLR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit^[1]Pomerantz Law Firm Reminds Investors with Losses on their Investment in Semler Scientific, Inc. of Class Action Lawsuit and Upcoming Deadlines - SMLR^[2]. The deadline to ask the court to appoint a lead plaintiff is October 28, 2025 Pomerantz Law Firm Reminds Investors with Losses on their Investment in Semler Scientific, Inc. of Class Action Lawsuit and Upcoming Deadlines - SMLR^[2].